China News Service, January 25. According to Euronet, a report from the Associated Press on the 25th, the British pharmaceutical company AstraZeneca has warned that the initial supply of the new crown vaccine to Europe will be lower than expected.
This has aroused concerns from all walks of life about promoting vaccination, forcing some European countries to draw up contingency plans due to the drastic reduction in vaccine delivery.
Among them, in Italy, delivery delays will delay the vaccination time for people over 80 by about 4 weeks, and the rest will be delayed by about 6 to 8 weeks.
In Palermo, Italy, people are vaccinated against the new crown in hospitals.
Image source: ICphoto
According to reports, AstraZeneca announced that the initial supply of the vaccine jointly developed with Oxford University will be lower than expected. The company also said that it will increase production in February and March.
Pfizer of the United States also announced last week that the vaccine jointly developed with BioNTech of Germany will be delayed by one month due to the expansion of the Belgian factory.
Kyriakidis, the European Union's executive commissioner for health services, said that this announcement caused deep dissatisfaction among EU member states and insisted on an accurate delivery schedule.
Italian Prime Minister Conte stated on social media platforms that the government is considering taking legal action against AstraZeneca’s unacceptable announcement.
On the 24th, Sileri, the Deputy Minister of Health of Italy, confirmed Prime Minister Conte’s statement in an interview with the media.
He said that Italy's vaccination plan is based entirely on the agreement reached between pharmaceutical companies and the European Union.
Sileri pointed out that delays in delivery will delay the vaccination time for people over 80 by about 4 weeks, and the rest will be delayed by about 6 to 8 weeks.
Sileri also said that the slowdown in the vaccination program involves most of Europe and the world.
To overcome the problems on the production line, it is necessary to reach a framework agreement within Europe, which should allow third-party representatives to operate, thereby establishing synergy between the currently operating company and other companies not currently engaged in vaccine production.